Paul Kleihues

List of Publications by Year
in descending order

Version: 2024-02-01

94 papers	41,661 citations	23567 58 h-index	45317 90 g-index
98 all docs	98 docs citations	98 times ranked	31721 citing authors

#	Article	IF	Citations
1	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 2016, 131, 803-820.	7.7	12,144
2	The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathologica, 2007, 114, 97-109.	7.7	9,898
3	The WHO Classification of Tumors of the Nervous System. Journal of Neuropathology and Experimental Neurology, 2002, 61, 215-225.	1.7	1,615
4	The New WHO Classification of Brain Tumours. Brain Pathology, 1993, 3, 255-268.	4.1	1,480
5	Genetic Pathways to Primary and Secondary Glioblastoma. American Journal of Pathology, 2007, 170, 1445-1453.	3.8	1,250
6	Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas. Journal of Neuropathology and Experimental Neurology, 2005, 64, 479-489.	1.7	1,174
7	Genetic Pathways to Glioblastoma. Cancer Research, 2004, 64, 6892-6899.	0.9	1,137
8	Epidemiology and etiology of gliomas. Acta Neuropathologica, 2005, 109, 93-108.	7.7	1,041
9	IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas. American Journal of Pathology, 2009, 174, 1149-1153.	3.8	877
10	The Definition of Primary and Secondary Glioblastoma. Clinical Cancer Research, 2013, 19, 764-772.	7.0	819
11	Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas. Brain Pathology, 1996, 6, 217-223.	4.1	664
12	IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clinical Cancer Research, 2009, 15, 6002-6007.	7.0	604
13	<scp>I</scp>nternational <scp>S</scp>ociety of <scp>N</scp>europathologyâ€<scp>H</scp>aarlem <scp>C</scp>onsensus <scp>G</scp>uidelines for <scp>N</scp>ervous <scp>S</scp>ystem <scp>T</scp>umor <scp>C</scp>lassification and <scp>G</scp>rading. Brain Pathology, 2014, 24, 429-435.	4.1	499
14	Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro-Oncology, 1999, 1, 44-51.	1.2	456
15	Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. Journal of Neurosurgery, 1988, 68, 698-704.	1.6	397
16	Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Science, 2009, 100, 2235-2241.	3.9	374
17	Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Research, 2003, 63, 6643-50.	0.9	350
18	HIVâ€Associated Disease of the Nervous System: Review of Nomenclature and Proposal for Neuropathologyâ€Based Terminology. Brain Pathology, 1991, 1, 143-152.	4.1	323

#	Article	IF	Citations
19	Central Neurocytoma: A Synopsis of Clinical and Histological Features. Brain Pathology, 1993, 3, 297-306.	4.1	306
20	Histopathology, classification, and grading of gliomas. Glia, 1995, 15, 211-221.	4.9	303
21	Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathologica, 2004, 108, 49-56.	7.7	288
22	Molecular Classification of Low-Grade Diffuse Gliomas. American Journal of Pathology, 2010, 177, 2708-2714.	3.8	218
23	A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. Journal of Neurosurgery, 2003, 98, 1170-1174.	1.6	215
24	Genetic Profile of Gliosarcomas. American Journal of Pathology, 2000, 156, 425-432.	3.8	212
25	PTEN (MMAC1) Mutations Are Frequent in Primary Glioblastomas (de novo) but not in Secondary Glioblastomas. Journal of Neuropathology and Experimental Neurology, 1998, 57, 684-689.	1.7	209
26	TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathologica, 2013, 126, 931-937.	7.7	209
27	Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Molecular Carcinogenesis, 1993, 8, 74-80.	2.7	205
28	p14^{ARF} Deletion and Methylation in Genetic Pathways to Glioblastomas. Brain Pathology, 2001, 11, 159-168.	4.1	197
29	Thep53 gene and its role in human brain tumors. Glia, 1995, 15, 308-327.	4.9	172
30	Promoter Hypermethylation of the RB1 Gene in Glioblastomas. Laboratory Investigation, 2001, 81, 77-82.	3.7	158
31	Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathology, 2011, 28, 177-183.	1.7	146
32	Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathologica, 1997, 94, 303-309.	7.7	145
33	Loss of Heterozygosity on Chromosome 10 Is More Extensive in Primary (De Novo) Than in Secondary Glioblastomas. Laboratory Investigation, 2000, 80, 65-72.	3.7	145
34	Amplification and Overexpression of MDM2 in Primary (de novo) Glioblastomas. Journal of Neuropathology and Experimental Neurology, 1997, 56, 180-185.	1.7	144
35	Fas Ligand Expression in Glioblastoma Cell Lines and Primary Astrocytic Brain Tumors. Brain Pathology, 1997, 7, 863-869.	4.1	142
36	Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies. Cancer, 1989, 63, 2014-2023.	4.1	135

#	Article	IF	Citations
37	Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas. Acta Neuropathologica, 2002, 103, 267-275.	7.7	126
38	Acquisition of the Glioblastoma Phenotype during Astrocytoma Progression Is Associated with Loss of Heterozygosity on 10q25-qter. American Journal of Pathology, 1999, 155, 387-394.	3.8	120
39	Loss of Heterozygosity on Chromosome 19 in Secondary Glioblastomas. Journal of Neuropathology and Experimental Neurology, 2000, 59, 539-543.	1.7	118
40	Predominant Expression of Mutant EGFR (EGFRvIII) is Rare in Primary Glioblastomas. Brain Pathology, 2004, 14, 131-136.	4.1	118
41	Molecular pathogenesis of astrocytic tumours. Journal of Neuro-Oncology, 2004, 70, 137-160.	2.9	114
42	PTEN methylation and expression in glioblastomas. Acta Neuropathologica, 2003, 106, 479-485.	7.7	113
43	Age as a Predictive Factor in Glioblastomas: Population-Based Study. Neuroepidemiology, 2009, 33, 17-22.	2.3	108
44	Phenotype vs Genotype in the Evolution of Astrocytic Brain Tumors. Toxicologic Pathology, 2000, 28, 164-170.	1.8	96
45	Identification in Human Brain Tumors of DNA Sequences Specific for SV40 Large T Antigen. Brain Pathology, 1999, 9, 33-42.	4.1	94
46	Concurrent Inactivation of RB1 and TP53 Pathways in Anaplastic Oligodendrogliomas. Journal of Neuropathology and Experimental Neurology, 2001, 60, 1181-1189.	1.7	92
47	p53 and PTEN gene mutations in gemistocytic astrocytomas. Acta Neuropathologica, 1998, 95, 559-564.	7.7	84
48	Promoter hypermethylation and homozygous deletion of the p14 ARF and p16 INK4a genes in oligodendrogliomas. Acta Neuropathologica, 2001, 101, 185-189.	7.7	79
49	Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children. Association with an activated K-ras gene. Cancer, 1992, 69, 2385-2392.	4.1	77
50	p53 mutations in primary human lung tumors and their metastases. Molecular Carcinogenesis, 1994, 9, 105-109.	2.7	72
51	Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathologica, 2009, 117, 653-656.	7.7	71
52	Genetics of Glioma Progression and the Definition of Primary and Secondary Glioblastoma. Brain Pathology, 1997, 7, 1131-1136.	4.1	69
53	Genetic and Expression Profiles of Cerebellar Liponeurocytomas. Brain Pathology, 2004, 14, 281-289.	4.1	69
54	Infrequent alterations of thep15, p16, CDK4 andCYCLIN D1 genes in non-astrocytic human brain tumors. International Journal of Cancer, 1996, 66, 305-308.	5.1	67

#	Article	IF	Citations
55	Intratumoral Patterns of Genomic Imbalance in Glioblastomas. Brain Pathology, 2010, 20, 936-944.	4.1	67
56	Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. Brain Pathology, 2016, 26, 517-522.	4.1	63
57	Necrogenesis and Fas/APO-1 (CD95) Expression in Primary (de novo) and Secondary Glioblastomas. Journal of Neuropathology and Experimental Neurology, 1998, 57, 239-245.	1.7	62
58	Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme. Acta Neuropathologica, 1996, 92, 431-434.	7.7	58
59	p53 gene mutations in oropharyngeal carcinomas: A comparison of solitary and multiple primary tumours and lymph-node metastases. International Journal of Cancer, 1994, 56, 807-811.	5.1	56
60	Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene, 2004, 23, 6012-6022.	5.9	56
61	p53 Mutations versus EGF Receptor Expression in Giant Cell Glioblastomas. Journal of Neuropathology and Experimental Neurology, 1997, 56, 1236-1241.	1.7	53
62	Hemizygous or homozygous deletion of the chromosomal region containing thep16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. , 1997, 73, 57-63.		48
63	Genetic profiling of CNS tumors extends histological classification. Acta Neuropathologica, 2010, 120, 269-270.	7.7	47
64	Hansâ€Joachim Scherer (1906â€1945), Pioneer in Glioma Research. Brain Pathology, 1999, 9, 241-245.	4.1	45
65	Methylation of the p73 gene in gliomas. Acta Neuropathologica, 2002, 104, 357-362.	7.7	43
66	Germline SDHD mutation in paraganglioma of the spinal cord. Oncogene, 2001, 20, 5084-5086.	5.9	40
67	Cerebral Protein Synthesis during Long-Term Recovery from Severe Hypoglycemia. Journal of Cerebral Blood Flow and Metabolism, 1986, 6, 42-51.	4.3	33
68	Chemical Neuro-Oncogenesis: Role of Structural DNA Modifications, DNA Repair and Neural Target Cell Population1. Progress in Tumor Research, 1984, 27, 1-16.	0.1	32
69	More About: Cell and Molecular Biology of Simian Virus 40: Implications for Human Infections and Disease. Journal of the National Cancer Institute, 2000, 92, 495-496.	6.3	30
70	Genetic evidence of the neoplastic nature of gemistocytes in astrocytomas. Acta Neuropathologica, 2001, 102, 422-425.	7.7	30
71	Definition of Primary and Secondary Glioblastomaâ€”Response. Clinical Cancer Research, 2014, 20, 2013-2013.	7.0	29
72	Carcinomas of the renal pelvis associated with smoking and phenacetin abuse:p53 mutations and polymorphism of carcinogen-metabolising enzymes. , 1998, 79, 531-536.		27

#	Article	IF	Citations
73	Tumor induction by ras and myc oncogenes in fetal and neonatal brain: modulating effects of developmental stage and retroviral dose. Acta Neuropathologica, 1993, 86, 456-65.	7.7	22
74	TP53, MSH4, and LATS1 Germline Mutations in a Family with Clustering of Nervous System Tumors. American Journal of Pathology, 2014, 184, 2374-2381.	3.8	22
75	Oskar and CÃ©cile Vogt, Lenin's Brain and the Bumbleâ€Bees of the Black Forest. Brain Pathology, 1992, 2, 363-364.	4.1	20
76	Kernicterus in an adult. Annals of Neurology, 1986, 19, 595-598.	5.3	18
77	Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them?. Frontiers in Neurology, 2012, 3, 188.	2.4	17
78	Second Primary Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2001, 60, 208-215.	1.7	16
79	Invasiveness in vitro and biological markers in human primary glioblastomas. Journal of Neuro-Oncology, 2001, 54, 1-8.	2.9	16
80	Ki-ras mutations in spontaneous and chemically induced renal tumors of the rat. Molecular Carcinogenesis, 1991, 4, 455-459.	2.7	15
81	Brain Tumors in S100Î²-v-erbB Transgenic Rats. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1111-1117.	1.7	13
82	HIV Encephalopathy: Incidence, Definition and Pathogenesis. Pathology International, 1991, 41, 197-205.	1.3	8
83	Alterations of theRRASandERCC1Genes at 19q13 in Gemistocytic Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2014, 73, 908-915.	1.7	7
84	Braf Mutations Initiate the Development of Rat Gliomas Induced by Postnatal Exposure to N-Ethyl-N-Nitrosourea. American Journal of Pathology, 2016, 186, 2569-2576.	3.8	7
85	The Development of Neuropathology at the Massachusetts General Hospital and Harvard Medical School. Brain Pathology, 1994, 4, 181-181.	4.1	5
86	Subsets of Glioblastoma: Clinical and Histological vs. Genetic Typing.. Brain Pathology, 1998, 8, 667-668.	4.1	5
87	Germline MSH6 Mutation in a Patient With Two Independent Primary Glioblastomas. Journal of Neuropathology and Experimental Neurology, 2017, 76, 848-853.	1.7	4
88	Immunohistochemical Assessments of P53 Protein Accumulation and Tumor Growth Fraction During the Progression of Astrocytomas. , 1996, , 255-262.		4
89	Reply to <scp>M</scp>arc <scp>S</scp>cherer. Brain Pathology, 2013, 23, 488-488.	4.1	3
90	The Art of Brain Tumour Classification -A Tribute to Lucien J. Rubinstein (1925â€“1990). Brain Pathology, 1990, 1, 55-59.	4.1	2

#	Article	IF	Citations
91	Toward methylation-based classification of central nervous system tumors. Neuro-Oncology, 2018, 20, 579-581.	1.2	2
92	Genetic basis of glioma progression. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2003, 79B, 78-85.	3.8	1
93	Infrequent alterations of the p15, p16, CDK4 and CYCLIN D1 genes in non-astrocytic human brain tumors. , 1996, 66, 305.		1
94	Genetic Pathways in the Evolution of Gliomas. , 2005, , 207-221.		0